Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

BNY Mellon survey: AIFMD will reduce choice and increase costs for fund managers and investors

Monday, July 22, 2013
Opalesque Industry Update - New research by BNY Mellon, the global leader in investment management and investment services, points to significant uncertainty about Alternative Investment Fund Managers Directive (AIFMD) requirements despite today’s first deadline for authorisation. BNY Mellon surveyed 70 respondents from Europe, Asia, the US and Latin America from companies with an accumulated total of over USD$5 trillion assets under management.

Key findings from the survey include:

• Half the survey respondents believe that uncertainty remains within their organisation, while a third reveal a fear of not complying on time and of negative financial implications.

• 50 per cent believe that their organisation will be disadvantaged in some way by AIFMD over the medium term. Only 18 per cent believe there to be a benefit.

• While 58 per cent have a project team in place to deal with the issue, 73 per cent do not expect to apply for authorisation before 2014.

• As the industry comes to terms with the implications of a heightened regulatory environment, respondents believe that initial AIFMD project/one-off costs will range from between US$300,000 to over US$1 million per institution.

• Regulatory reporting is seen to have the greatest time and cost implications, followed by risk and compliance reporting. Respondents remain uncertain about the cost of depository services, which are not included in the estimates above. Additionally, 88 per cent believe that the cost of funds (TER) will increase as a result of AIFMD.

• 67 per cent believe that AIFMD will result in the absolute number of alternative funds decreasing, while 39 per cent believe that their organisation will close some funds, move funds outside of the EU or merge funds together.

• Two thirds of survey respondents believe the cost and complexity of compliance will lead to reduced choice of opportunities for investors.

• While fund managers do not expect to be the winners in this regulatory change, those surveyed believe that the key benefits of AIFMD will be seen mostly by investors and in the industry’s ability to distribute more widely, making funds more accessible to the end user. 54 per cent of respondents expect to see an increase in the amount of capital invested in alternative funds due to AIFMD.

• The findings indicate that over half of respondents do not expect the AIFMD requirements to be adopted by other jurisdictions. 62 per cent believe that investors will keep their money in European-domiciled funds rather than invest in jurisdictions with less onerous requirements.

“Despite today being the deadline to apply for authorisation under AIFMD, much work remains for the industry to achieve full compliance, with our research suggesting that the burden of regulation could even lead to a lower number of funds available to investors,” observes Hani Kablawi, EMEA Head of Asset Servicing at BNY Mellon, in response to today’s findings. “Despite attempts to improve investor access and information, the industry is challenged by the complexity of implementing AIFMD and the need to comply with it in the future. This is a demanding time for the industry as it grapples with the slew of further regulation under implementation or discussion across Europe.”

BNY Mellon ‘AIFMD-ready’ to support fund managers

BNY Mellon is ‘AIFMD-ready’ and able to provide full depositary services to asset managers impacted by the new Alternative Investment Fund Managers Directive (AIFMD), which comes into force today.

AIFMD will impact non-UCITS funds, with implications for managers both inside and outside of the EU (dependent on their distribution of funds within the EU). The Directive seeks to harmonise and make compulsory the regulation of Alternative Investment Fund Managers (AIFM) based within the EU or who sell their products to EU investors. The AIFMD aims to create greater transparency and investor protection by aligning the management and safekeeping of Alternative Investment Fund (AIF) assets to the rules governing UCITS (Undertakings for Collective Investment in Transferable Securities) funds. Early applicants will be able to leverage the AIFMD passport opportunities for cross-border European distribution.

“Over the last 18 months we have invested strongly in our European infrastructure and personnel so that we are ready to support those clients who become authorized early under the Directive,” noted Hani Kablawi, EMEA Head of BNY Mellon’s Asset Servicing business. “Whilst the new regulation has added a greater level of complexity to our work as a depositary to Alternative Investment Funds, the solutions that we have in place will allow our clients to continue to operate efficiently and cost effectively within the new environment.”

“There is no doubt AIFMD represents a significant change for the funds industry across Europe and beyond,” added Peter Craft, BNY Mellon’s EMEA Head of Trustee and Depositary Services. “It transforms our duties and introduces significant new liabilities. We are leveraging the strength of our team across Europe to ensure we are ready to support managers in this pressurized operating environment.”

Press release

www.bnymellon.com

Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its